Eman Hamdy

Dr. Eman Hamdy

orcid

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 November 2020 in Multiple Sclerosis and Related Disorders
Verified
Journal Article
Closed access
FTFarouk Talaat
Farouk Talaat
IRIsmail Ramadan
Ismail Ramadan
SASalma Aly
Salma Aly
EHEman Hamdy
Eman Hamdy

8 September 2022 in European Radiology Experimental
Verified
Journal Article
Open access
PDF file
EHEman Hamdy
Eman Hamdy
AGAya Abdel Galeel
Aya Abdel Galeel
IRIsmail Ramadan
Ismail Ramadan
DGDina Gaber
Dina Gaber
HMHaytham Mustafa
Haytham Mustafa
JMJaidaa Mekky
Jaidaa Mekky
Background: Though abnormal iron deposition has been reported in specific brain regions in multiple sclerosis (MS), no data exist about whether the overall quantity of iron in the brain is altered or not. We aimed to determine whether the noted aberrant iron deposition in MS brains was a problem of overall load or regional distribution in a cohort of MS patients.Methods: An experienced neuroradiologist, a radiology software engineer, and four neurologists analysed data from quantitative susceptibility maps reconstructed from 3-T magnetic resonance brain images of 30 MS patients and 15 age- and sex-matched healthy controls. Global brain iron load was calculated, and the regional iron concentrations were assessed in 1,000 regions of interest placed in MS lesions in different locations, normal appearing white matter, thalami, and basal ganglia.Results: Global brain iron load was comparable between patients and controls after adjustment for volume (p= 0.660), whereas the regional iron concentrations were significantly different in patients than in control (p≤ 0.031). There was no significant correlation between global iron load and clinical parameters, whereas regional iron concentrations correlated with patients’ age, disease duration, and disability grade (p≤ 0.039).Conclusions: The aberrant iron deposition noted in MS seems to be a problem of regional distribution rather than an altered global brain iron load.

1 June 2020 in Epilepsy & Behavior
Verified
Journal Article
Closed access
MHMohamed M. Hamdy
Mohamed M. Hamdy
AEAmr M. Elfatatry
Amr M. Elfatatry
JMJaidaa Farouk Mekky
Jaidaa Farouk Mekky
EHEman Hamdy
Eman Hamdy

29 December 2023 in Journal of Clinical Medicine
Verified
Journal Article
Open access
PDF file
SLSotiria Stavropoulou De Lorenzo
Sotiria Stavropoulou De Lorenzo
Christos BakirtzisChristos Bakirtzis
Christos Bakirtzis
NKNatalia Konstantinidou
Natalia Konstantinidou
EKEvangelia Kesidou
Evangelia Kesidou
DPDimitrios Parissis
Dimitrios Parissis
NGNikolaos Grigoriadis
Nikolaos Grigoriadis
The development and further optimization of the diagnostic criteria for multiple sclerosis (MS) emphasize the establishment of an early and accurate diagnosis. So far, numerous studies have revealed the significance of early treatment administration for MS and its association with slower disease progression and better late outcomes of the disease with regards to disability accumulation. However, according to current research results, both neuroinflammatory and neurodegenerative processes may exist prior to symptom initiation. Despite the fact that a significant proportion of individuals with radiologically isolated syndrome (RIS) progress to MS, currently, there is no available treatment approved for RIS. Therefore, our idea of “early treatment administration” might be already late in some cases. In order to detect the individuals who will progress to MS, we need accurate biomarkers. In this review, we present notable research results regarding the underlying pathology of MS, as well as several potentially useful laboratory and neuroimaging biomarkers for the identification of high-risk individuals with RIS for developing MS. This review aims to raise clinicians’ awareness regarding “subclinical” MS, enrich their understanding of MS pathology, and familiarize them with several potential biomarkers that are currently under investigation and might be used in clinical practice in the future for the identification of individuals with RIS at high risk for conversion to definite MS.

5 March 2022 in Multiple Sclerosis and Related Disorders
Verified
Journal Article
Closed access
EHEman Hamdy
Eman Hamdy
FTFarouk Talaat
Farouk Talaat
IRIsmail Ramadan
Ismail Ramadan
HMHazem Marouf
Hazem Marouf
MHMohamed Mohamed Hamdy
Mohamed Mohamed Hamdy
SSSameh Mahmoud Said
Sameh Mahmoud Said

17 September 2024 in BMC Neurology
Verified
Journal Article
Open access
PDF file
MHMohamed Mohamed Hamdy
Mohamed Mohamed Hamdy
NNNada Nasr
Nada Nasr
EHEman Hamdy
Eman Hamdy
Though an association between cluster headache (CH) and smoking has been postulated, data from the Middle East region is scarce. To study the relationship between smoking and CH clinical characteristics and responsiveness to therapy in Egypt. This was a prospective cohort hospital-based study conducted on patients with episodic and chronic CH in a tertiary headache clinic in Egypt during the period between 2019 and 2023. Patients were consecutively recruited at the time of their presentation and were followed up for two weeks after initiation of prophylactic treatment and steroids (as transitional therapy). Of 172 patients with CH recruited, 144 (83.7%) were smokers. Twenty-eight patients (16.3%) had chronic CH. The mean age was 42.08 ± 10.93 (20–66) years, and 131 (76.2%) were males. Smokers had a significantly higher median number of cluster bouts in the past five years (3.0 (IQR2.0–4.0) versus 2.0 (IQR 1.0–2.0)) and worse HIT-6 scores [51.0 (44.0–59.75) versus 41.0 (38.0–41.75)] than non-smokers (p < 0.001). The number of cluster bouts in the past five years was positively correlated with the smoking index (r = 0.249 (p = 0.006) and the smoking duration (in years) (r = 0.392 (p < 0.001)). HIT-6 scores were significantly correlated with the age at smoking onset (r=-0.190, = 0.023), smoking index (r = 0.519, p < 0.001), smoking duration (r = 0.611, p < 0.001), and number of cigarettes consumed per day (r = 0.392, p < 0.001). Smoking is significantly correlated with the daily frequency of CH attacks, the frequency of CH bouts in the past five years, and the HIT-6 scores among our cohort.